Cosyntropin is a synthetic peptide made of the first 24 amino acids of ACTH, the pituitary hormone that drives cortisol. It is a diagnostic agent, used to check whether the adrenal glands can respond. This guide covers its structure, mechanism, FDA-labeled use, key evidence and label warnings. Sources were checked on November 17, 2026.
Quick answer: Cosyntropin is a prescription diagnostic agent sold as Cortrosyn and as generics. Its label covers screening for adrenocortical insufficiency in adults and children, together with other tests. It is not a treatment. The label has no boxed warning; hypersensitivity, including anaphylaxis, is the main warning.
Vitrapep does not sell cosyntropin; this page is a reference summary of published research and regulatory information.
What is cosyntropin?
Cosyntropin is a shortened, lab-made copy of adrenocorticotropic hormone (ACTH). The Cortrosyn label says it contains “the first 24 of the 39 amino acids of natural ACTH.” It describes cosyntropin as an open-chain polypeptide and as a synthetic beta 1-24 corticotropin (Cortrosyn label, 2025).
It is a peptide because it is a single chain of 24 amino acids. That is well under FDA’s cutoff for a protein, which is “greater than 40 amino acids in size” (21 CFR 600.3). PubChem lists the formula C136H210N40O31S and a molecular weight of 2,933.4 g/mol (PubChem CID 16129617). Our peptide primer explains the basics.
Drugs@FDA lists the original approval of Cortrosyn (NDA 016750) on April 22, 1970, now held by Amphastar (Drugs@FDA). Current cosyntropin labels, including Cortrosyn and a Sandoz generic, give 2008 as the “Initial U.S. Approval” year. The sources we checked do not explain that difference.
Cosyntropin: key facts
| Fact | Detail |
|---|---|
| Structure type | Linear (open-chain) peptide of 24 amino acids, matching ACTH 1-24 |
| Class | Synthetic ACTH fragment; diagnostic agent |
| Molecular formula | C136H210N40O31S |
| Molecular weight | 2,933.4 g/mol |
| First FDA approval | April 22, 1970 (Cortrosyn, NDA 016750); labels state 2008 as initial U.S. approval |
| Brand names (US) | Cortrosyn; generic cosyntropin from Sandoz and others |
How does cosyntropin work?
The first 24 amino acids of ACTH carry its activity on the adrenal glands. The Cortrosyn label states: “Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH.” Its profile is similar to purified natural ACTH, and it stimulates the adrenal cortex to the same maximal extent (Cortrosyn label, 2025).
That makes it a test of adrenal reserve. A healthy adrenal cortex answers the signal by making cortisol. A failing one does not. The label’s warning on diagnostic accuracy notes that cortisol levels drive the diagnosis. Natural ACTH products such as Acthar Gel are a different thing. They are porcine-derived mixtures used as treatments, covered in our corticotropin guide (Acthar label, 2026).
What is cosyntropin approved for?
The Cortrosyn label states that it “is indicated, in combination with other diagnostic tests, for use as a diagnostic agent.” The intended use is “the screening of adrenocortical insufficiency in adults and pediatric patients.” The Sandoz generic label carries the same indication (Sandoz cosyntropin label, 2024). Adrenocortical insufficiency means the adrenal glands do not make enough cortisol.
What does the key evidence show?
Because cosyntropin is a diagnostic, the key question is accuracy: how well does the test sort people with and without adrenal insufficiency? Primary adrenal insufficiency starts in the adrenal glands. Secondary adrenal insufficiency starts in the pituitary, which stops sending enough ACTH.
Pooled diagnostic analysis. A 2003 review searched MEDLINE from 1966 to 2002 and pooled human study data into summary ROC curves. At 95% specificity, the standard cosyntropin test had 97% sensitivity for primary adrenal insufficiency. For secondary adrenal insufficiency, sensitivity fell to 57%. A lower-stimulus version of the test reached 61%. The authors wrote that “the cosyntropin test performs well in patients with primary adrenal insufficiency” (Dorin et al., 2003).
For secondary disease, they advised tests that stimulate the hypothalamus when suspicion is high enough. The label likewise frames cosyntropin as one test used with others.
What side effects does the label list?
The Cortrosyn label has no boxed warning. Its only contraindication is a history of hypersensitivity to cosyntropin or its excipients. Its adverse reactions come from post-approval reports, so the label notes their frequency cannot be reliably estimated. The reported reactions are:
- anaphylactic reaction;
- slow or fast heart rate (bradycardia, tachycardia);
- high blood pressure; and
- peripheral edema and rash.
The label has two warnings. The first is hypersensitivity, including anaphylaxis. The second is diagnostic inaccuracy: medicines and conditions that change cortisol or cortisol-binding globulin levels can skew results (Cortrosyn label, 2025).
What is cosyntropin’s regulatory status, and how is it used in research?
Cosyntropin is a prescription diagnostic agent in the United States. Cortrosyn is marketed under an NDA; the Sandoz product is an ANDA generic (ANDA 202147). DailyMed lists Cortrosyn from Amphastar, generics from Sandoz and others, and listings from Medical Purchasing Solutions and HealthFirst. It also lists Cosacthen, a veterinary cosyntropin product from Dechra Veterinary Products (DailyMed, 2026). The evidence summarized here comes from human diagnostic studies.
Frequently asked questions about cosyntropin
Is cosyntropin a peptide?
Yes. It is a synthetic 24-amino-acid peptide matching the first 24 amino acids of ACTH.
Is cosyntropin a treatment?
No. Its label covers use as a diagnostic agent to screen for adrenocortical insufficiency, alongside other tests.
When was cosyntropin approved?
Drugs@FDA lists the original approval of Cortrosyn on April 22, 1970.
How is cosyntropin different from Acthar Gel?
Cosyntropin is a synthetic 24-amino-acid fragment used for testing. Acthar Gel is a porcine-derived mixture built around full-length ACTH and used as a treatment.
Does cosyntropin have a boxed warning?
No. Its warnings are hypersensitivity, including anaphylaxis, and factors that can make test results inaccurate.
What to know now
- Structure: synthetic ACTH 1-24 peptide; C136H210N40O31S; 2,933.4 g/mol.
- Approval: Cortrosyn, April 22, 1970 (Drugs@FDA); prescription diagnostic only.
- Mechanism: full corticosteroidogenic activity of natural ACTH on the adrenal cortex.
- Evidence: 97% sensitivity for primary and 57% for secondary adrenal insufficiency at 95% specificity.
- Safety: no boxed warning; anaphylaxis and diagnostic inaccuracy are the warnings.
What we’re watching
Further Cortrosyn label revisions on DailyMed, last revised in February 2025. Related guides: corticotropin, pasireotide and secretin, another peptide used as a diagnostic.